Effects of telmisartan on lipid profile and on proinflammatory factors in patients with essential hypertension and abdominal obesity

We evaluated effects of telmisartan on serum lipids, CRP, TNF-? levels, and quality of life in patients with arterial hypertension and abdominal obesity. We studied 23 patients, aged 51,1 ± 0,9 years old. Dose of telmisartan was 40 mg per day during 2 months. Systolic blood pressure decreased from 153,8 ± 4,5 to 122,6 ± 2,4 mm Hg (p < 0,0001), and diastolic -from 94,0 ± 2,5 to 78,8 ± 2,0 mm Hg (p < 0,001) after 8 weeks of therapy. Serum cholesterol and low-density lipoprotein levels also decreased (from 5,9 ± 0,3 to 5,6 ± 0,3 mM; p < 0,05; and from 3,8 ± 0,3 to 3,4 ± 0,2 mM; p < 0,03; respectively). Serum CRP signifi cantly decreased after therapy (8,7 ± 4,1 versus 4,9 ± 2,0 mg/l; p < 0,05). The level of TNF-? tended to decrease. Treatment with telmisartan improved quality of life in all patients.

arterial hypertension , abdominal obesity , telmisartan , lipids , infl ammation

1. Sikaris K.A. The clinical biochemistry of obesity // Clin. Biochem. Rev. - 2004. - Vol. 25. - P. 165-181.

2.

3. Демидова Т.Ю. Ожирение и инсулинорезистентность // Трудный пациент. - 2006. - № 7. - C. 25-28.

4.

5. Pi-Sunyer F. The obesity epidemic: pathophysiology and consequences of obesity // Obes. Res. - 2002. - Vol. 10. - S. 97-104.

6.

7. Speakman J. Obesity: the integrated roles of environment and genetics // J. Nutr. - 2004. - Vol. 134. - P. 2090-2105.

8.

9. Grundy S.M., Brewer H.B., Cleeman J.I. et al. For the сonference зarticipants: defi nitionof metabolic syndrome. Report of the National Heart, Lung and Blood Institute. AHA Conference of scientifi c issues related to defi nition // Circulation. - 2004. - Vol. 109. - P. 433-438.

10.

11. Napoli D.M., Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with fi rst-ever ischemic stroke // Stroke. - 2003. - Vol. 34. -P. 2922-2929.

12.

13. Pi-Sunyer F. The medical risks of obesity // Obes. Surg. - 2002. -Vol. 12, Suppl. 1. - P. 6-11.

14.

15. You T., Yang R., Lyles M.F. et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors // Am. J. Physiol. Endocrinol. Metab. - 2005. - Vol. 288. - P. 741-747.

16.

17. Асташкин Е.И., Глезер М.Г. Ожирение и aртериальная гипертония // Пробл. женского здоровья. - 2008. - Т. 3, № 4. - С. 23-33.

18.

19. Gorzelniak K., Engeli S., Janke J. et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension // J. Hypertens. - 2002. - Vol. 20. - P. 965-973.

20.

21. Paul M., Mehr A.P., Kreutz R. Physiology of local renin-angiotensin systems // Physiol. Rev. - 2006. - Vol. 86. - P. 747-803.

22.

23. Fliser D., Buchholz K., Haller H. For the European Trial on Olmesartan and Pravastatin in Infl ammation and Atherosclerosis (EUTOPIA) // Invest. Circul. - 2004. - Vol. 110. - P. 1103-1107.

24.

25. Touyz R.M. Intracellular mechanisms involved in vascular remodeling of resistance arteries in hypertension: role of angiotensin II // Exp. Physiol. - 2005. - Vol. 90, № 4. - P. 449-455.

26.

27. Cao J.J., Arnold A.M., Manolio T.A. et al. Association of carotid intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality. The cardiovascular heart study // Circulation. - 2007. - Vol. 116. - P. 32-38.

28.

29. De Buyzere M.L., Rietzschel E-R. C-reactive protein's place on the cardiovascular stage: prima ballerina or chorus girl? // J. Hypertens. -2006. - № 24. - P. 627-632.

30.

31. Wang C-H., Li S-H., Weisel R.D., et al. C-reactive protein upregu-lates angiotensin type 1 receptors in vascular smooth muscle // Circulation. - 2003. - № 107. - P. 1783-1790.

32.

33. Fitchett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion // Vasc. Health Risk Manag. - 2009. - № 5. -P. 21-529.

34.

35. Rizos C.V., Elisaf M.S., Liberopoulos E.N. Are the pleiotropic effects of telmisartan clinically relevant? // Curr. Pharm. Des. - 2009. -Vol. 15, № 24. - P. 2815-2832.

36.

37. Мычка В.Б., Душивши Д.Э., Мамырбаева К.М. и др. Место телмисартана в лечении метаболического синдрома // Терапевт. арх. -2006. - Т. 78, № 8. - C. 63-67.

38.

39. Yamagishi S., Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property // Med. Hypotheses. - 2005. - Vol. 64, № 3. - P. 476-478.

40.

41. Alberti G. Introduction to the metabolic syndrome // Eur. Heart J. 2005. - № 7 (Suppl. D). - P. D3-D5.

42.

43. Благосклонная Я.В., Шляхто Е.В., Бабенко А.Ю. Эндокринология: Уч. для мед. вузов. - Спб.: СпецЛит, 2004. - 398 с.

44.

45. Byrne D. The EU and the obesity epidemic // Eurohealth. -2003. - Vol. 9, № 1. - P. 16-17.

46.

47. Sharma A.M., Davidson J., Koval S. et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study // Cardiovasc. Diabetol. - 2007. - Vol. 2. - P. 6-28.

48.

49. Филатова Т.Е., Пчелинцев В.П., Давыдов В.В. и др. Опыт применения телмисартана (Микардиса) у пациентов с сахарным диабетом 2 типа, диабетической нефропатией и артериальной гипертензией // Рос. мед.-биол. вестн. им. акад. И.П. Павлова. - 2007. - № 4. -C. 113-116.

50.

51. Dahlöf B. Prevention of stroke in patients with hypertension // Am. J. Cardiol. - 2007. - Vol. 6, № 100 (3A). - P. 17-24.

52.

53. Shibuya Y, Ikeda T, Gomi T. Morning rise of blood pressure assessed by home blood pressure monitoring is associated with left ventricular hypertrophy in hypertensive patients receiving long-term antihypertensive medication // Hypertens. Res. - 2007. - Vol. 30, № 10. - P. 903-911.

54.

55. Takano H., Komuro I. Peroxisome proliferator-activated receptor γ and cardiovascular diseases // Circ. J. - 2009. - Vol. 73. - P. 214-220.

56.

57. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator // Acta Diabetol. - 2005. - Vol. 42, Suppl. 1. - P. 9-16.

58.

59. Benson S.C., Iguchi R., Ho C.I. et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? // J. Hypertens. - 2008. - Vol. 26, № 5. - S. 973-980.

60.

61. Kobayashi N. et. al. Cardioprotective mechanism of telmisarta via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats // Am. J. Hypertens. - 2008. - Vol. 21, № 5. - P. 576-581.

62.

63. Manabe S., Okura T, Watanabe S. et al. Effects of angiotensin II receptor blockade with valsartan on pro-infl ammatory cytokines in patients with essential hypertension // J. Cardiovasc. Pharmacol. - 2005. - Vol. 46, № 6. - P. 735-739.

64.

65. Tian Q., Miyazaki R., Ichiki T. et al. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through crosstalk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta // Hypertension. -2009. - Vol. 53, № 5. - P. 798-804.

66.

67. Best L.G, Zhang Y, Lee E.T. et al. C-reactive protein as a predictor of cardiovascular risk in a population with a highprevalence of diabetes. The Strong Heart Study // Circulation. - 2005. - № 112. -P. 1289-1295.

68.

69. Miura Y, Yamamoto N., Tsunekawa S. et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences // Diabetes Care. - 2005. - Vol. 28, № 3. - P. 757-758.

70.

71. Chujo D., Yagi K., Asano A. et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular infl ammation markers in Japanese hypertensive patients // Hypertens. Res. - 2007. - Vol. 30, № 12. - P. 1205-1210.

72.

73. Sardo M.A., Castaldo M., Cinquegrani M. et al. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients // Angiology. - 2004. - Vol. 55, № 2. - P. 195-203.

74.

75. Lottermoser K., Ulrich-Merzenich G, Vetter H. et al. Effects of angiotensin II on infl ammation mediators in healthy subjects // Dtsch. Med. Wochenschr. - 2003. - Vol. 21, № 128 (47). - P. 2470-2475.

76.

77. Fliser D., Buchholz K., Haller H. For the European Trial on Olmesartan and Pravastatin in Infl ammation and Atherosclerosis (EUTOPIA) // Invest. Circul. - 2004. - Vol. 110. - P. 1103-1197.

78.

79. Okano Y., Tamura K., Masuda S. et al. Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life // Clin. Exp. Hypertens. - 2009. - Vol. 31, № 8. - P. 680-689.

80.

81. Андреева Г.Ф., Горбунов В.М., Айвазян ТА. и др. Влияние телмисартана на психологический статус и качество жизни больных со стабильной артериальной гипертензией // Эксперимент. и клинич. фармакол. - 2004. - Т. 67, № 6. - С. 36-40.

82.

83. Weber M.A., Bakris G.L., Neutel J.M. et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker // J. Clin. Hypertens. (Greenwich). - 2003. - Vol. 5, № 5. - P. 322-329.